Furthermore, in MSS GC patients, high LATS1/2 and FOXP3 expressions and low CD8 expression predicted adverse patient prognoses, whereas in MSI GC, only CD8 predicted patient prognoses. This evidence concerns the gene CD8A and gastric cancer.